Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
In 2013, Brazil’s total pharmaceutical market for type 2 diabetes rivaled the size of some of the major markets. Increasing public awareness, an aging population, and the launch of new premium-priced antidiabetic agents will all contribute to the growth of this market in the next five years. The large, growing prevalent population promises a 7% annual growth in sales and significant opportunity for multinational pharmaceutical companies as demand for branded antidiabetic drugs continues to grow throughout Brazil.
Primary research: 92 endocrinologist and primary care physician surveys across Brazil. Separate in-depth interviews with 8 medical experts.
Epidemiology: Prevalence of type 2 diabetes in Brazil. Age- and gender-specific ten-year epidemiology forecast (2013-2023).
Market forecast features: Our analysis evaluates the size of the patient population, percentage of diagnosed patients, and percentage of drug-treated patients. We include a detailed forecast for antidiabetic drug classes and leading products from 2013-2018 using a combination of historical trend analysis and an epidemiology-based bottom-up market model.
Already a Client? Log in to access this report.